Display options
Cite
Law E, Gavanji R, Walsh S, et al. Palbociclib versus abemaciclib in HR+/HER2- advanced breast cancer: an indirect comparison of patient-reported end points. J Comp Eff Res. 2021;doi: 10.2217/cer-2021-0221.
Law, E., Gavanji, R., Walsh, S., Haltner, A., McTavish, R., & Cameron, C. (2021). Palbociclib versus abemaciclib in HR+/HER2- advanced breast cancer: an indirect comparison of patient-reported end points. Journal of comparative effectiveness research, . https://doi.org/10.2217/cer-2021-0221
Law, Ernest, et al. "Palbociclib versus abemaciclib in HR+/HER2- advanced breast cancer: an indirect comparison of patient-reported end points." Journal of comparative effectiveness research vol. (2021). doi: https://doi.org/10.2217/cer-2021-0221
Law E, Gavanji R, Walsh S, Haltner A, McTavish R, Cameron C. Palbociclib versus abemaciclib in HR+/HER2- advanced breast cancer: an indirect comparison of patient-reported end points. J Comp Eff Res. 2021 Nov 09; doi: 10.2217/cer-2021-0221. Epub 2021 Nov 09. PMID: 34751591.
Copy Download .nbib Format: NLM
Share it on

J Comp Eff Res. 2021 Nov 09; doi: 10.2217/cer-2021-0221. Epub 2021 Nov 09.

Palbociclib versus abemaciclib in HR+/HER2- advanced breast cancer: an indirect comparison of patient-reported end points.

Journal of comparative effectiveness research

Ernest Law, Roya Gavanji, Sarah Walsh, Anja Haltner, Rebecca McTavish, Chris Cameron

Affiliations

  1. Pfizer, New York, NY 10017, USA.
  2. EVERSANA, Burlington, Ontario L7N 3H8, Canada.
  3. EVERSANA, Sydney, Nova Scotia B1P 1C6, Canada.

PMID: 34751591 DOI: 10.2217/cer-2021-0221

[No abstract available.]

Keywords: HER2-negative; abemaciclib; advanced breast cancer; health-related quality of life; hormone receptor-positive; indirect treatment comparison; matching-adjusted indirect comparison; palbociclib; patient-reported outcomes; quality of life

Publication Types

Grant support